Journal
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 95, Issue 1, Pages 135-143Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2008.001628
Keywords
CD20; monoclonal antibodies; lymphoma; immunotherapy
Categories
Funding
- MRC
- Leukaemia Research
- Medical Research Council [G0800457] Funding Source: researchfish
- MRC [G0800457] Funding Source: UKRI
Ask authors/readers for more resources
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available